Sino Biopharm's penpulimab injection approved for US market

Sino Biopharmaceutical Limited (HKEX:1177) announced that its co-developed penpulimab injection has been approved by the United States Food and Drug Administration (US FDA) for marketing. The drug is indicated for the treatment of recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC) in adults. Specifically, it is approved for first-line treatment in combination with cisplatin or carboplatin and gemcitabine, and as a single agent for those with disease progression after platinum-based chemotherapy.